Longevity Health Holdings: Significant Business Updates Unveiled
PITTSBURGH and GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) — Longevity Health Holdings, Inc. (Nasdaq: XAGE), a pioneering force in extending human longevity through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition, has announced a series of pivotal business updates designed to enhance its offerings and operational framework.
1. Merger Agreement with 20/20 BioLabs
On April 11, 2025, XAGE executed a merger agreement with 20/20 BioLabs, a strategic move that will position 20/20 as a wholly-owned subsidiary of XAGE upon fulfilling the merger’s stipulated conditions. In thrilling developments, an S-4 prospectus was officially filed with the Securities and Exchange Commission (SEC) on May 8, 2025, marking a significant step in their corporate strategy.
2. Unaudited Q1 Sales Performance
The company’s unaudited Q1 sales figures reflect a promising trajectory:
- XAGE: Approximately $663,000 on a full quarter pro forma basis, showcasing an impressive 8% increase compared to last year.
- 20/20: Approximately $562,000, registering a robust 15% year-over-year increase.
3. Reverse Stock Split Executed
XAGE completed a 1 for 30 reverse stock split of its common stock on May 12, 2025. Following this adjustment, trading began at the newly set price on May 14, 2025, aligning the stock’s value with strategic financial goals.
4. Anticipated Q2 Product Launches
Exciting product launches are on the horizon for Q2:
- XAGE plans to introduce a medicated cleanser designed specifically for use in physicians’ offices and MedSpas, further tapping into 20/20’s diverse customer base.
- 20/20 is set to launch a new lab test focusing on inflammatory biomarkers in the blood, a vital tool for understanding premature aging and associated health disorders.
- Additionally, 20/20 announced a collaborative initiative with Giant Food across nine stores in Maryland and Virginia to offer OneTestTM, which screens for multiple cancers using capillary blood, with potential plans to expand further.
5. Increased Financing Initiatives
As both companies drive forward with their innovative product lines and operational strategies, they actively seek additional financing avenues to support their growth trajectories.
About 20/20 BioLabs
20/20 BioLabs excels in devising and commercializing advanced laboratory tests aimed at the early detection and proactive management of chronic diseases. Their groundbreaking multi-cancer early detection blood test is accessible throughout the U.S., available for home collection or at retail locations. In the upcoming quarter, 20/20 plans to introduce a revolutionary blood test to monitor chronic inflammation, directly addressing eight of the top ten leading causes of death in America.
About Longevity Health Holdings
Longevity Health Holdings concentrates on promoting longevity and healthy aging, leveraging the latest scientific advancements in regenerative bio-aesthetics, diagnostics, and nutrition. The company proudly offers cutting-edge regenerative technologies aimed at optimizing skin and hair health, including the Carmell Secretome™ and Elevai ExosomesTM.
Looking Ahead
This exciting array of updates positions Longevity Health Holdings and 20/20 BioLabs at the forefront of health and wellness innovation. Investors and health enthusiasts alike should stay tuned for transformative developments on their journey toward enhancing human longevity and health.
Forward-Looking Statements
This press release contains forward-looking statements based on beliefs, assumptions, and current information. While the company believes it possesses a reasonable basis for such statements, actual results could differ materially due to various risks and uncertainties.
Additional Information
This communication does not constitute an offer to sell or solicit an offer to buy any securities concerning the proposed transaction. For a full understanding, parties are encouraged to review the official filings with the SEC.
For more information about XAGE and to access filed documents, please visit XAGE’s website. Contact: Bryan Cassaday at [email protected].
